Imatinib Stada

Imatinib, the active ingredient in Imatinib Stada, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients. GNH USA supplies Imatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib is a targeted tyrosine‑kinase inhibitor used in several hematologic and solid‑tumor indications. - Chronic myeloid leukemia (CML): suppresses BCR‑ABL driven leukemic cell proliferation and helps achieve durable remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to disease control and improves survival when combined with chemotherapy. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT and PDGFR signaling, reducing tumor growth and disease progression.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: reduced energy levels and general tiredness. - Edema: swelling, often in the extremities.

Serious or Rare Side Effects: - Neutropenia: significant drop in white blood cells increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: reduced heart function presenting with dyspnea or edema.

Patients should be monitored closely for known safety concerns. - Blood counts: regular CBC to detect neutropenia or anemia. - Liver function: periodic LFTs to identify hepatotoxicity early. - Cardiac status: assess for signs of heart failure, especially in at‑risk individuals. - CYP3A4 inhibitors: avoid strong inhibitors that may raise imatinib exposure. - Pregnancy: discuss potential risks with a specialist; use only if benefits outweigh risks. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with several co‑administered medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): can markedly increase plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy by lowering drug exposure. - Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Digoxin: possible increase in serum concentration; observe for toxicity.